Lithuanian University of Health Sciences Research Management System (CRIS)





DSpace-CRIS 8

Recent Additions
  • preprint
    Prill, Robert
    ;
    Janosky, Joseph
    ;
    Bode, Lisa
    ;
    van Melick, Nicky
    ;
    Villa, Francesco Della
    ;
    Becker, Roland
    ;
    Karlsson, Jon
    ;
    ;
    Gokeler, Alli
    ;
    Jones, Henrique
    ;
    Seil, Romain
    ;
    Tscholl, Philippe
    ;
    Patt, Thomas
    Knee Surgery, Sports Traumatology, Arthroscopy, 2025-04-22, vol. 00, no. 00, p. 1-5
  • conference paper not in proceedings;
    Nicolau, C.
    ;
    ; ;
    Lopeta, M.
    ;
    ; ;
    RSNA 2024 Annual Meeting "Building Intelligent Connections" : December 1-5, 2024, 2024-12-05, p. 1-1

    Purpose: This study aimed to investigate the accuracy of magnetic resonance imaging (MRI), genetic urinary test (GUT) and prostate cancer prevention trial risk calculator version 2.0 (PCPTRC2) for the clinically significant prostate cancer (csPCa) diagnostic in biopsynaïve patients. *Methods and Materials: In a single center study between 2021 and 2024 participants underwent prostate mpMRI, GUT and ultrasound (US) guided biopsy. The csPCa risk was calculated using PCPTRC2. Post digital rectal examination (DRE) GUT was performed measuring RNA levels of PCA3 and T:E fusion genes. The McNemar test compared detection rates between modalities. Results: 208 (mean age 62.9 years +/- 8.2) men were included prospectively. A positive GUT score was found in 67.8% and PIRADS ≥3 in 81.7% of all cases. The combination of GUT with mpMRI showed significantly higher sensitivity (99.1%) than GUT and mpMRI alone, 84.4% and 93.8%, respectively (p ≤ 0.05). Similarly, very high sensitivity (99.0%) was achieved by combining mpMRI with PCPTCR2. Nevertheless, mpMRI plus GUT combination exceeded mpMRI plus PCPTCR2 by allowing to save a higher fraction of unnecessary biopsies, 25% and 2,4%, respectively. Conclusions: GUT and mpMRI combination would allow saving a substantial fraction of unnecessary biopsies with minimal risk of missing csPCa cases. Clinical Relevance/Application: The combination of genetic urinary testing (GUT) and MRI enhanced the detection sensitivity of csPCa while substantially reducing unnecessary biopsies, thereby improving diagnostic efficiency and patient outcomes.

  • conference poster not in proceedings; ; ; ;
    Congress European Society of Radiology - ECR 2023 „The Cycle of Life“ : Vienna, Austria, July 5-9, 2023 : EPOS™ - Scientific and Educational Poster Exhibition, 2023-07-05, p. 1-1

    Purpose: The diagnosis and management of prostate cancer are evolving every year. Digital rectal examination (DRE) and prostate specific antigen (PSA) screening are usually followed by subsequent DRE-directed or transrectal ultrasound (TRUS)-guided biopsy sampling. However, this technique allows to detect prostate cancer only 30% to 40% of cases. Men undergoing TRUS-guided biopsy are at risk of several complications, including lower urinary tract symptoms (up to 25% of cases), hematuria, rectal bleeding, hematospermia, infection, pain, urinary retention, erectile dysfunction and even mortality. Avoiding unnecessary biopsy is critical to protect men to undergo an uncomfortable and potentially risky invasive procedure and to avoid labeling them with a cancer diagnosis which is highly related to psychological stress.

    Magnetic resonance imaging (MRI) use in daily prostate cancer detection is increasing and has proven to be a valuable tool in cancer diagnostics. Multiparametric MRI (MpMRI) in prostate cancer patients has demonstrated better diagnosis while performing targeted biopsy and decreased diagnosis of clinically insignificant prostate cancer.

    Urine is a versatile body fluid for non-invasive urological malignancies detection. It is known, that prostate cancer biomarkers are likely to be found in urine sample because of the anatomical localization of the prostate next to the bladder apex and the proximal part of the urethra. The most investigated biomarkers are PCA3 and TMPRSS2:ERG fusion. PCA3 is a – a prostate specific long non-coding RNR overexpressed in 95% of prostate cancer cases. TMPRSS2:ERG is androgen regulated gene fusion which is believed to play a major role in prostate tumorogenesis.

    Non-invasive methods, such as urinary biomarkers’ detection along with mpMRI could be more suitable for diagnostics of prostate cancer in biopsy-naïve patients. The objective of this study was to evaluate mpMRI, genetic urinary test (GUT) separately and in combination as an indicator of early significant prostate cancer (PCa). [...].

  • conference paper
    Haq, Ayman
    ;
    ; ;
    Miedema, Michael
    Circulation : Abstracts From the American Heart Association's 2024 Scientific Sessions and the American Heart Association's 2024 Resuscitation Science Symposium, 2024-11-11, vol. 150, no. Suppl. 1, p. 1-1

    Introduction: Adherence to statin therapy is suboptimal in the primary prevention population, despite extensive data regarding efficacy and safety. Hypothesis: Introducing autonomy in the decision-making process will increase statin adherence and reduce perceived side effects. Goals: Compare six-month rate of statin adherence and perceived side effects in patients who initially decline atorvastatin, between those given reassurance and those offered a supplement trial prior to statin therapy. Methods: Patients > 40 years without a history of ASCVD at a moderate ASCVD risk who decline statin therapy underwent block randomization. The control group was provided education and reassurance regarding the statin therapy and prescribed 30mg atorvastatin. The intervention group was offered a trial of red yeast rice extract 20mg and a goal LDL-C 100 mg/dL. After 2 months those not at the goal LDL-C were then prescribed 30mg atorvastatin (Figure 1). The primary endpoint was the number of monthly pharmacy refills at 6 months. The secondary endpoints were rates of self-reported myalgias, fatigue, mental fog, and gastrointestinal upset at 6 months. The Wilcoxon rank sum test and the Chi-square test was used to assess the primary and secondary endpoints, respectively. Results: The final analysis included 276 patients; baseline demographics, labs and lipid profiles were similar between the two groups. Statin prescriptions filled was higher in the intervention group (Figure 2). The intervention group had lower rates of fatigue and mental fog, but not myalgias or gastrointestinal upset (Figure 3). Conclusion: Introducing autonomy in the decision-making process improved adherence to atorvastatin therapy and reduced the rate of perceived side effects.

Most viewed
  • Universitetas / University
      9241
  • Researcher
    Stankutė, Deimantė
    Istorija / History
    Some of the metrics are blocked by your 
      6921
  • Researcher
    Kavaliauskaitė, Agnė
    Istorija / History
    Some of the metrics are blocked by your 
      5392  2
  • Some of the metrics are blocked by your 
      5239
  • journal article
    Lietuvos bendrosios praktikos gydytojas. Kaunas : Vitae Litera, 2008, t. 12, Nr. 10., p. 679-681.

    Lėtinis atrofinis gastritas – tai ilgalaikio lėtinio skrandžio uždegimo sąlygota skrandžio gleivinės atrofija. Atrofinio gastrito fone vystosi metaplazija žarninio tipo epiteliu, vėliau epitelio displazija ir skrandžio vėžys. Atrofija ir žarninė metaplazija apibūdinamos kaip ikivėžinės būklės. Skrandžio gleivinės atrofija ir žarninė metaplazija yra dažnesnės šalyse, kuriose yra didelis sergamumas skrandžio vėžiu. Atrofinis gastritas laikomas ikivėžine liga, tačiau nėra visiškai aišku, ar galimas atrofijos proceso sustabdymas, ar tai leidžia apsaugoti nuo skrandžio vėžio.

      4640
Most downloaded